Publications by authors named "Christian Oliver C Co"
Phase II randomised, double-blind, placebo-controlled trial to assess the efficacy and safety of MLC1501 in patients with stroke: the MLC1501 study Assessing Efficacy in post-STrOke Subjects with mOtor deficits (MAESTOSO) study protocol.
Stroke Vasc Neurol
February 2025
Background: MLC1501, consisting of four herbs, that is, , , , , has the same pharmacological properties as its precursors MLC601 and MLC901 which contain extracts of nine herbs and showed neuroprotective, anti-inflammatory and neurorestorative properties in non-clinical models, as well as clinical benefits in improving functional and neurological recovery after brain injuries.
Aims: To determine the efficacy of MLC1501 on motor recovery as measured by Fugl-Meyer motor Assessment (FMA) total score at 24 weeks in patients with ischaemic stroke (IS).
Design: A total of 300 patients aged >18 years, diagnosed with IS in the prior 2-10 days, with National Institute of Health Stroke Scale (NIHSS) total score of 8-18 and a combined score of ≥3 on NIHSS motor items 5A, 5B, 6A and/or 6B, will be randomised in a 1:1:1 ratio to receive oral placebo, MLC1501 low dose or MLC1501 high dose for 6 months.
Article Synopsis
- The COVID-19 pandemic has posed challenges for medical teams managing acute stroke patients, who may not show typical COVID-19 symptoms, making timely intervention essential without sacrificing safety.
- The stroke team evaluated pre-pandemic protocols and identified challenges during the pandemic, leading to the development of a revised acute stroke care algorithm tailored to local resources and practices.
- The new algorithm emphasizes coordination among healthcare professionals, the effective use of personal protective equipment, and the integration of telemedicine, thus improving resource management and stroke care during the pandemic, potentially benefiting other settings with similar limitations.
Background And Purpose: Reversing the effect of dabigatran among patients with atrial fibrillation is important to normalize coagulation profile among patients who develop serious hemorrhage from any source. However, such intervention always has the potential to cause a prothrombotic state. Among patients suspected of ischemic stroke, Idarucizumab, may be administered preceding thrombolysis.
View Article and Find Full Text PDFThe 2019 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) which was first reported in Wuhan, China last December 2019, has been declared an emergency by the World Health Organization but eventually progressed to become a Pandemic. To date, Coronavirus Disease 2019 (COVID-19) has affected at least 100,000 individuals worldwide, reaching thousands of mortalities (Zhou et al., 2020; World Health Organization, 2020).
View Article and Find Full Text PDF